Vis enkel innførsel

dc.contributor.authorHelgeland, Erik
dc.contributor.authorWergeland, Anita
dc.contributor.authorSandøy, Rune Kringstad
dc.contributor.authorAskeland, Maren Haave
dc.contributor.authorAspevik, Anne
dc.contributor.authorBreivik, Lars Ertesvåg
dc.contributor.authorJonassen, Anne K
dc.date.accessioned2017-09-05T10:58:41Z
dc.date.available2017-09-05T10:58:41Z
dc.date.created2017-04-28T11:21:41Z
dc.date.issued2017
dc.identifier.citationScandinavian Cardiovascular Journal. 2017, 51 (3), 159-166.nb_NO
dc.identifier.issn1401-7431
dc.identifier.urihttp://hdl.handle.net/11250/2453182
dc.description.abstractObjectives. Pharmacological treatment of reperfusion injury using insulin and GSK3β inhibition has been shown to be cardioprotective, however, their interaction with the endogenous cardioprotective strategy, ischemic postconditioning, is not known. Design. Langendorff perfused ex vivo rat hearts were subjected to 30 min of regional ischemia and 120 min of reperfusion. For the first 15 min of reperfusion hearts received either vehicle (Ctr), insulin (Ins) or a GSK3β inhibitor (SB415286; SB41), with or without interruption of ischemic postconditioning (IPost; 3 × 30 s of global ischemia). In addition, the combination of insulin and SB41 for 15 min was assessed. Results. Insulin, SB41 or IPost significantly reduced infarct size versus vehicle treated controls (IPost 33.5 ± 3.3%, Ins 33.5 ± 3.4%, SB41 30.5 ± 3.0% vs. Ctr 54.7 ± 6.8%, p < 0.01). Combining insulin and SB415286 did not confer additional cardioprotection compared to the treatments given alone (SB41 + Ins 26.7 ± 3.5%, ns). Conversely, combining either of the pharmacological reperfusion treatments with IPost completely abrogated the cardioprotection afforded by the treatments separately (Ins + IPost 59.5 ± 3.4% vs. Ins 33.5 ± 3.4% and SB41 + IPost 50.2 ± 6.6% vs. SB41 30.5 ± 3.0%, both p < 0.01), and was associated with blunted Akt, GSK3β and STAT3 phosphorylation. Conclusion. Pharmacological reperfusion treatment with insulin and SB41 interferes with the cardioprotection afforded by ischemic postconditioning.nb_NO
dc.language.isoengnb_NO
dc.publisherTaylor & Francisnb_NO
dc.titleInsulin and GSK3β-inhibition abrogates the infarct sparing-effect of ischemic postconditioning in ex vivo rat heartsnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionacceptedVersionnb_NO
dc.source.pagenumber159-166nb_NO
dc.source.volume51nb_NO
dc.source.journalScandinavian Cardiovascular Journalnb_NO
dc.source.issue3nb_NO
dc.identifier.doi10.1080/14017431.2017.1288920
dc.identifier.cristin1467181
dc.description.localcodeThis is an Accepted Manuscript of an article published by Taylor & Francis in Scandinavian Cardiovascular Journal on 13 Feb 2017, available online: http://www.tandfonline.com/doi/full/10.1080/14017431.2017.1288920 . Locked until 13 Feb 2018 due to copyright restrictions.nb_NO
cristin.unitcode194,18,23,20
cristin.unitnameSeksjon for sykepleie
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel